Trial Information

Single Nucleotide Polymorphisms (SNP) in Platinum-/Radiation Pathway Genes to Predict Outcome in Patients With Esophageal Adenocarcinoma Treated With Cisplatin-Based Chemoradiotherapy Followed by Surgical Resection

OBJECTIVES:

- Correlate patient outcomes with neoplastic cell genotypes, specifically 18 single
nucleotide polymorphisms (SNPs) in 16 major genes involved in platinum metabolism and
disposition and DNA repair, in patients with esophageal cancer treated with neoadjuvant
cisplatin-based chemoradiotherapy followed by surgical resection on clinical trial
ECOG-1201.

- Correlate patient outcomes with neoplastic cell genotypes, specifically loss of
heterozygosity, in these patients.

- Correlate patient outcomes with normal (germline) cell genotypes, specifically SNPs
related to platinum metabolism and disposition and DNA repair.

- Compare the predictive ability of neoplastic vs germline cell genotypes.

OUTLINE: This is a retrospective, cohort, multicenter study.

Neoplastic and normal (germline) cells are collected from pretreatment and post-treatment
specimens using laser-capture microdissection. Single nucleotide polymorphisms are examined
by real-time PCR. Loss of heterozygosity is assessed by analyzing short tandem repeat
markers in neoplastic and germline tissue.